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Abstract This review describes the preclinical mecha-
nisms that may underlie the increased therapeutic benefit
of combination therapy—with the N-methyl-D-aspartate
receptor antagonist, memantine, and an acetylcholinesterase
inhibitor (AChEI)—for the treatment of Alzheimer’s disease
(AD). Memantine, and the AChEIs target two different
aspects of AD pathology. Both drug types have shown sig-
nificant efficacy as monotherapies for the treatment of AD.
Furthermore, clinical observations indicate that their com-
plementary mechanisms offer superior benefit as combina-
tion therapy. Based on the available literature, the authors
have considered the preclinical mechanisms that could
underlie such a combined approach. Memantine addresses
dysfunction in glutamatergic transmission, while the AC-
hEIs serve to increase pathologically lowered levels of
the neurotransmitter acetylcholine. In addition, preclinical
studies have shown that memantine has neuroprotective
effects, acting to prevent glutamatergic over-stimulation and
the resulting neurotoxicity. Interrelations between the
glutamatergic and cholinergic pathways in regions of the
brain that control learning and memory mean that combi-
nation treatment has the potential for a complex influence on
disease pathology. Moreover, studies in animal models have
shown that the combined use of memantine and the AChEIs
can produce greater improvements in measures of memory
than either treatment alone. As an effective approach in the
clinical setting, combination therapy with memantine and an
AChEI has been a welcome advance for the treatment of
patients with AD. Preclinical data have shown how these
drugs act via two different, but interconnected, pathological
pathways, and that their complementary activity may pro-
duce greater effects than either drug individually.
Keywords Acetylcholine  Alzheimer’s disease 
Cholinesterase inhibitors  Glutamate  Mechanism of
action  Memantine
Introduction
Alzheimer’s disease (AD) is the most common form of
dementia. The prevalence of AD is strongly correlated with
increasing age, and is a consequence of progressive neu-
rodegeneration occurring over a period of several years, or
even decades. This neurodegeneration leads to a gradual
decline in cognitive, functional and behavioural processes,
producing characteristic symptoms such as memory loss,
confusion, agitation, and difficulties performing the activ-
ities of daily living. The symptoms become more severe
over time, creating a decline in independence and an
increasing reliance on caregiver support. By the end stages
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of AD, the patient is frequently bedridden, with substantial
impairments (if not complete loss) of continence, swal-
lowing, eating, speech, and motor abilities.
Extensive research into the underlying disease processes
of AD has identified common pathological changes, with a
leading hypothesis centring on neurotoxic protein deposits
in the brain (amyloid plaques, neurofibrillary tangles). These
are accompanied by disruptions in neurotransmitter levels,
neuronal cell death, and brain (cortical) atrophy. Amyloid
plaques consisting mainly of insoluble amyloid-beta pep-
tide, and are a key histopathological feature of the AD brain.
However, it has been proposed that the soluble oligomers of
amyloid-beta, rather than the insoluble deposits, are pri-
marily responsible for neurodegeneration and the impair-
ment of synaptic function—including an effect on
glutamatergic signalling pathways (see below) (De Felice
et al. 2007; Lacor et al. 2007). Subsequently, pathological
changes in neurotransmission can be associated with the
characteristic clinical symptoms observed in AD. For
example, in AD, there are impairments in glutamatergic and
cholinergic signalling, which are involved in learning and
memory processes in healthy individuals. Dysfunction in the
glutamatergic system may lead to direct impairment of
cognition and, in the long term, neuronal loss. Glutamate is
responsible for approximately 70 % of the excitatory neu-
rotransmission in the central nervous system (CNS), par-
ticularly in the cortical and hippocampal regions (Danysz
et al. 2000). When the N-methyl-D-aspartate (NMDA)
receptor is activated by glutamate, calcium (Ca2?) ions flow
into the post-synaptic neurone (Dingledine et al. 1999). In a
normal physiological situation, this triggers a signalling
cascade that produces synaptic plasticity such as long-term
potentiation (LTP) (Cacabelos et al. 1999), and thereby
facilitates the higher order processes of learning and mem-
ory. According to some hypotheses, in AD, NMDA recep-
tors are constantly over-activated, leading to sustained Ca2?
influx (Cacabelos et al. 1999; Danysz and Parsons 2003;
Parsons et al. 1993). This creates a pathological ‘background
noise’ against which normal physiological glutamate sig-
nalling cannot be detected (Danysz and Parsons 2003).
Furthermore, prolonged Ca2? overload in the post-synaptic
neurones generates a form of ‘slow excitotoxicity’, pro-
ducing a gradual neurodegenerative effect (Cacabelos et al.
1999; Danysz and Parsons 2003; Kornhuber and Weller
1997; Lancelot and Beal 1998; Parsons et al. 1998). It is
probable that this pathological over-activity is due to
increased resting glutamate concentrations, as well as
increased receptor sensitivity to resting glutamate levels
(Albin and Greenamyre 1992; Danysz and Parsons 2003).
Certainly, some evidence suggests that various toxins, act-
ing through NMDA receptors, e.g. amyloid-beta oligomers,
can produce increased sensitivity and/or tonic activity of
glutamate receptors, leading to neuronal death (De Felice
et al. 2007; Lacor et al. 2007; Nyakas et al. 2011; Szegedi
et al. 2005; Wenk et al. 2006; Wu et al. 1995) and decreasing
synaptic plasticity (Nakagami and Oda 2002). In addition to
this glutamatergic pathology, amyloid-beta peptides have
also been shown to depress the release, synthesis, and axonal
transport of acetylcholine (ACh) (Auld et al. 2002; Nyakas
et al. 2011).
Cholinergic dysfunction in the basal and rostral forebrain
is associated with even early cognitive impairments
observed in AD, correlates with cognitive decline, and forms
the basis of the ‘cholinergic hypothesis’ of AD (Perry et al.
1999; Terry and Buccafusco 2003). The involvement of the
cholinergic system in AD was further strengthened by pre-
clinical studies in which cholinergic antagonists were shown
to impair memory in animals, and studies in which damage/
lesions that interfered with cholinergic input from the basal
forebrain (to the neocortex and hippocampus) led to memory
deficits in both animals and humans (reviewed in Terry and
Buccafusco 2003). In humans, several studies of scopol-
amine (a pan-muscarinic receptor antagonist) have indicated
that cholinergic neurotransmission is pivotal to normal
memory acquisition, facilitating immediate recall (Drach-
man 1977; Mewaldt and Ghoneim 1979; Petersen 1977)—
possibly by preventing proactive interference between
stored information and new memory (Atri et al. 2004).
Furthermore, analyses of biopsy samples from the neocortex
found that choline uptake, choline acetyltransferase activity
and resulting ACh synthesis were all markedly reduced in
patients with AD—indicating a loss of presynaptic cholin-
ergic nerve endings (Sims et al. 1983). Overall, it is
hypothesised that the degeneration of cholinergic neurones
leads to a decline in the level of ACh, and the resulting
weakened signalling contributes to cognitive decline and
memory impairment in AD (Francis et al. 1985; Sims et al.
1983; Terry and Buccafusco 2003; Turrini et al. 2001). In
addition, AD brains have a reduced number of cholinergic
neuronal nicotinic receptor ion channels (a7 and a4b2)
(Nordberg 2001) and functional uncoupling of cholinergic
muscarinic M1 (G-protein coupled) receptors (Joseph et al.
1993; Thathiah and De Strooper 2009).
Reflecting these pathological patterns, the two drug
classes currently available for the treatment of AD are the
uncompetitive NMDA receptor antagonist, memantine
(which normalises dysfunctional glutamatergic neuro-
transmission), and acetylcholinesterase inhibitors (AChEIs:
donepezil, galanthamine and rivastigmine, which all raise
ACh levels). As monotherapies, these drug types have
demonstrated significant symptomatic efficacy in AD, and
existing clinical data suggest that their combined use may
bring additional benefit. For example, in a randomised,
controlled clinical study of patients with moderate to
severe AD, treatment with memantine and donepezil pro-
duced significant symptomatic (cognitive, functional,
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behavioural and global) advantages over donepezil mono-
therapy (Tariot et al. 2004). There are also indications that
combined treatment could produce long-term benefits, and
favourably influence time to nursing home admission (Atri
et al. 2008; Lopez et al. 2009).
Here, we discuss the potential mechanisms that may
underlie these clinical observations, including the scientific
rationale for targeting two different neurotransmitter sys-
tems to achieve additive clinical effects.
Mechanism of Action: Memantine
Memantine is indicated for the treatment of patients with
moderate to severe AD, and has shown significant symp-
tomatic efficacy in several large-scale, controlled clinical
studies (Reisberg et al. 2003; Tariot et al. 2004; Winblad
et al. 2007). There is also evidence that memantine may be
effective in delaying clinical worsening, and decreasing the
emergence of behavioural symptoms including agitation and
aggression (Wilcock et al. 2008; Wilkinson and Andersen
2007).
Memantine has been characterised as an uncompetitive,
voltage-dependent NMDA receptor antagonist, with mod-
erate binding affinity, and rapid blocking–unblocking
receptor kinetics (Danysz et al. 2000; Parsons et al. 1993).
This unique binding profile enables memantine to integrate
in the glutamatergic signalling system, and influence dys-
functional NMDA receptor activation in AD. Under normal,
resting, physiological conditions, NMDA receptor channels
are blocked by magnesium (Mg2?) ions. Upon the arrival of a
strong transient glutamate synaptic signal, the post-synaptic
membrane becomes depolarised, relieving the voltage-
dependent Mg2? channel block, and the NMDA channel
opens to allow Ca2? ion flow into the post-synaptic neurone.
However, it has been suggested that in AD, due to glutamate
and amyloid-beta driven constant low-level stimulation
there is a decrease in membrane potential, removing the
NMDA receptor channel blockade by Mg2? ions, increasing
the continuous flow of Ca2? ions into the post-synaptic
neurone, and thereby creating a ‘background noise’ of
stimulation at rest. Electrophysiological studies have indi-
cated that memantine binds within the ion channel of the
NMDA receptor (Chen et al. 1992; Parsons et al. 1993).
Importantly, memantine binds with moderate affinity and
voltage dependency, which means that at moderate levels of
prolonged stimulation (i.e. under pathological conditions)
memantine continues to block the NMDA receptor chan-
nel—unlike the weaker binding Mg2? ion (Albrecht et al.
2008; Parsons et al. 1993, 1999a, 2007). However, when high
concentrations of glutamate are transiently present (i.e. when
a physiological signal arrives), memantine dissociates from
the receptor, and normal neurotransmission proceeds (Al-
brecht et al. 2008; Frankiewicz and Parsons 1999; Parsons
et al. 1999a, 2007). Thus, in AD, memantine may reduce the
pathological ‘background noise’ of dysfunctional glutamate
signalling, allowing physiological signals to be better dis-
tinguished (Danysz et al. 2000). Furthermore, in vivo and
in vitro testing has shown that this effect translates into a
reversal of learning impairments induced by over-activation
of NMDA receptors (e.g. Zajaczkowski et al. 1997).
In addition to this facilitation of signalling processes,
preclinical investigations indicate that memantine’s
mechanism may also serve to protect neurones from the
excitotoxicity of excessive glutamate stimulation. This has
been demonstrated in vitro (Parsons et al. 1999a, b), and
in vivo where memantine protected against excitotoxicity
induced by direct or indirect over-activation of NMDA
receptors (Keilhoff and Wolf 1992; Misztal et al. 1996;
Wenk et al. 1994, 1995; Willard et al. 2000).
As mentioned earlier, the presence of amyloid-beta has
been linked with pathological effects on the glutamatergic
system, indirectly triggering excess tonic levels of gluta-
mate in and around the synaptic cleft by inhibiting the
astroglial glutamate transporter (Nyakas et al. 2011) and
reducing glutamate reuptake (Harris et al. 1996; Noda et al.
1999). According to some authors, amyloid-beta peptides
may also stimulate NMDA receptors either as a direct
agonist, or secondary to interactions with, e.g. post-syn-
aptic anchoring proteins (De Felice et al. 2007; Mattson
et al. 1993; Szegedi et al. 2005; Wu et al. 1995).
Linking in with the ‘amyloid-beta hypothesis’, me-
mantine has been shown to protect against pathological
changes and learning deterioration induced by intra-hip-
pocampal injection of amyloid-beta (Miguel-Hidalgo et al.
2002). Moreover, memantine restored deficits in cognition,
and reduced levels of insoluble and soluble amyloid-beta
peptide in triple-transgenic mice with AD-like pathology
(Martinez-Coria et al. 2010). Memantine has also specifi-
cally demonstrated protection against amyloid-beta-
induced synaptic deterioration (Lacor et al. 2007) and
generation of reactive oxygen species (De Felice et al.
2007; Klein et al. 2007). Despite these findings the way in
which memantine’s mechanisms link to its clinical efficacy
in AD has still not been fully characterised.
Mechanism of Action: Acetylcholinesterase Inhibitors
The AChEIs (donepezil, galanthamine and rivastigmine)
are indicated for the treatment of AD from the mild stages
onwards (Birks 2009; Wilkinson et al. 2004). By inhibiting
the action of the ACh-hydrolyzing enzyme acetylcholin-
esterase (AChE—the predominant cholinesterase in the
brain), the AChEIs aim to boost ACh levels and thus
alleviate disease symptoms associated with the progressive
loss of cholinergic function in AD. Studies have shown that
lowered synthesis of ACh (including reduced choline
360 Neurotox Res (2013) 24:358–369
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acetyltransferase activity, required for ACh synthesis) is
associated with greater cognitive impairment in dementia,
including AD (Francis et al. 1985; Perry et al. 1978). In
contrast, raised ACh concentrations in the brain have been
shown to increase the expression of nicotinic ACh recep-
tors on cholinoceptive neurones (Barnes et al. 2000), and
are also linked to improved function of other neurotrans-
mitter systems associated with cognitive function, e.g.
glutamate (Dijk et al. 1995; Francis et al. 1993). Therefore,
AChE inhibition was identified as a useful therapeutic
strategy to enhance cholinergic neurotransmission, even
though patients with advanced AD show reductions in
AChE levels of up to 90 % (Giacobini 2003). Clinical
support for this treatment approach comes from multiple
clinical studies in which AChEIs have benefited patients’
cognitive, functional and global status (Birks 2009).
However, despite clear evidence of efficacy in the clinical
setting, the exact mechanisms and pathways that link
AChE inhibition and ACh activity with symptomatic
improvements in AD are not fully understood.
Although the three AChEIs display no notable differ-
ences in their clinical efficacy (Birks 2009), their under-
lying mechanisms can be distinguished in terms of target
protein specificity. Donepezil is a specific and reversible
inhibitor of AChE (Davidsson et al. 2001; Wilkinson et al.
2004), and also independently interacts with neuronal
nicotinic ACh receptors (Di Angelantonio et al. 2004). In
contrast, rivastigmine is a pseudo-irreversible inhibitor of
AChE (Davidsson et al. 2001; Weinstock 1999) (i.e. via a
temporary covalent bond), and has a similar level of
affinity for butyrylcholinesterase (BuChE) (Weinstock
1999; Wilkinson et al. 2004). BuChE is a non-specific
enzyme that can hydrolyse ACh and other choline esters,
and which is most predominant outside the CNS, with brain
levels increasing in severe AD (Giacobini et al. 1989;
Weinstock 1999; Wilkinson et al. 2004). Galanthamine is a
selective, reversible inhibitor of AChE and is claimed to
enhance the intrinsic action of ACh on nicotinic receptors,
with a potential link to amyloid-beta clearance (Popa et al.
2006; Takata et al. 2010; Wilkinson et al. 2004)—although
this latter effect is controversial. It does not seem that these
different specificities contribute substantially to any dif-
ferentiation in the therapeutic effects of the AChEIs
(Wattmo et al. 2011).
Combining the Action of Memantine and the AChEIs
As described above, memantine and the AChEIs target two
different pathological aspects of AD—the dysfunctional
glutamatergic and cholinergic transmitter systems, respec-
tively. The combined use of memantine and an AChEI in
the treatment of AD is therefore a logical, rational
approach, although the underlying mechanisms and
interactions are likely to be complex and partially reci-
procal as their signalling pathways are interconnected and
multiplexed.
Connections in the Glutamatergic and Cholinergic
Pathways
There is considerable evidence supporting the link between
the cholinergic and glutamatergic pathways, including their
relationship in the pathology of AD. Glutamatergic neu-
rones in the amygdala, reticular formation, hippocampus
and cerebral cortex make synaptic connections with cho-
linergic neurones located in the medial septum, diagonal
band of Broca and the nucleus basalis of Meynert (NbM).
These cholinergic neurones, in turn, innervate the neocor-
tex and hippocampus (Fig. 1a) (Bigl et al. 1982; Carnes
et al. 1990; Fadel et al. 2001; Fournier et al. 2004; Francis
et al. 1985, 1993; Mesulam and Mufson 1984; Moor et al.
1996; Wu et al. 2004). There is also evidence that synaptic
activation of NMDA receptors stimulates synaptic ACh
release from basal forebrain neurones (Fournier et al. 2004;
Moor et al. 1996), although these findings are somewhat
controversial (Fadel et al. 2001; Giovannini et al. 1994). In
addition, some ‘cholinergic’ neurones of the basal fore-
brain appear to release both ACh and glutamate (Allen
et al. 2006).
Enhancement of ACh transmission and/or activation of
nicotinic/muscarinic acetylcholine receptors increases LTP
in most regions of the hippocampus, where glutamatergic
pyramidal neurones provide the major intrinsic projection
pathways (Drever et al. 2011; Kenney and Gould 2008).
NMDA, amyloid-beta, and a decrease in Mg2? ions, all
impair LTP in the hippocampus; an effect that is prevented
by the action of memantine (Frankiewicz and Parsons
1999; Klyubin et al. 2011; Martinez-Coria et al. 2010;
Parsons et al. 1999a).
In terms of neurodegeneration, excessive activation of
glutamate receptors (particularly NMDA-type receptors)
has been implicated in processes underlying the degener-
ation of cholinergic cells in AD (Greenamyre and Young
1989). For example, neuronal degeneration caused by
direct injection of NMDA into the rat basal forebrain leads
to reduced levels of choline acetyltransferase activity in the
cortex, and this effect is prevented by memantine (Wenk
et al. 1994, 1995). Furthermore, memantine rescues basal
forebrain cholinergic neurones from the toxic effects of
amyloid-beta peptides, and attenuates amyloid-beta-
induced cholinergic fibre loss in the parietal neocortex
(Fig. 1b) (Nyakas et al. 2011).
Therefore, it seems that cholinergic neurones are vul-
nerable to the hyperactivity of the glutamate/NMDA
receptor system, while glutamatergic neurones may be both
the cause and the subsequent target of neuronal degeneration.
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Preclinical Data on the Combined Action of Memantine
and the AChEIs
In light of the interplay between the glutamatergic and
cholinergic pathways, the combined use of memantine and
the AChEIs has been examined in several preclinical
studies. Importantly, investigations in vitro, in vivo and
ex vivo have shown that memantine does not attenuate the
AChE blockade produced by therapeutically relevant con-
centrations of clinically used AChEIs (Enz and Gentsch
2004; Gupta and Dekundy 2005; Wenk et al. 2000).
With regard to combined efficacy, the effect of meman-
tine plus donepezil on cognitive deficits was examined in
triple-transgenic mice exhibiting cognitive impairment and
high brain levels of amyloid-beta plaques and neurofibrillary
tangles (Martinez-Coria et al. 2009). In 6- and 15-month-old
transgenic mice, memantine, and the combination of do-
nepezil and memantine, significantly improved spatial
memory (acquisition and retention) (Martinez-Coria et al.
2009). Donepezil treatment alone significantly improved the
retention (but not the acquisition) of spatial memory in
younger mice, but no significant effects were seen in older
mice (Martinez-Coria et al. 2009). In both age groups, the
memantine–donepezil combination was the only treatment
that significantly improved latency to reaching the platform
location (Martinez-Coria et al. 2009).
The combined effects of memantine and donepezil on
spatial memory were also specifically examined in the
APP23 mouse model using a complex dry-land maze test
(Neumeister and Riepe 2012). In 4.5-month-old APP23
mice with cognitive deficits, treatment with memantine
plus donepezil produced significant improvements in both
resting time and moving time, which were greater than
those observed with either treatment alone (Neumeister and
Riepe 2012). Notably, treatment with memantine alone
produced a significant improvement in resting time, but not
moving time, and donepezil treatment improved moving
time, but not resting time (Neumeister and Riepe 2012).
These findings led the authors to suggest that combination
treatment with memantine and donepezil was exerting a
synergistic effect on spatial learning ability in these ani-
mals, with the individual drugs acting differentially: me-
mantine addressing resting time (possibly reflecting
memory retrieval), and donepezil influencing moving time
(possibly reflecting memory acquisition) (Neumeister and
Riepe 2012).
3-Neurone Model
Based on available preclinical evidence of the actions of
memantine and the AChEIs, the 3-neurone model is pro-
posed to explain the better efficacy of combination
treatment.
It is established that memantine and the AChEIs inter-
vene at separate points of the disrupted signalling cascades
in AD. Acting at the NMDA receptor, memantine lowers
the pathologically increased tonic level of excitation of the
glutamatergic synapse at rest (neurone 2—see Fig. 2). This
is likely to have a twofold impact: firstly, it reduces the
background noise, so that incoming physiological signals
can be better distinguished; secondly, it reduces the con-
stant pathological influx of Ca2?, and thereby helps to
prevent the neurone being stimulated in a way that would
cause both dysfunction, synaptotoxicity and ultimately cell
death (neurone 2) (Parsons et al. 1999a, 2007). Overall,
tonic NMDA receptor activation is reduced, which delays
Fig. 1 Links between the glutamatergic and cholinergic pathways
362 Neurotox Res (2013) 24:358–369
123
the neurodegeneration of cholinergic neurones bearing
NMDA receptors, and synaptic NMDA receptor activation
is facilitated (Fig. 3). Supplementing this effect, the AC-
hEIs may serve to amplify (i.e. bring towards normal) the
pathologically weakened signal from cholinergic neurones
by delaying ACh breakdown at cholinergic nerve endings
(reviewed in Palmer and Gershon 1990). In this way,
neurotransmission (to neurone 3) is preserved, with the
improved signal detected against the lowered background
noise (Fig. 2). Together, such effects would help to main-
tain the glutamatergic/cholinergic signalling cascades, and
consequently facilitate LTP and memory processes.
Clearly, this model is an integrated and simplified view
of what is known to be a highly complex system. In par-
ticular, the 3-neurone model does not take into account that
neurotransmission is unlikely to be a simple one-direc-
tional process. In practice, glutamatergic neurones not only
make synaptic connections with cholinergic neurones, but
cholinergic neurones also influence glutamatergic trans-
mission in areas such as the cortex and hippocampus.
Therefore, applied together, memantine and AChEIs have
the potential to act at different places in interconnected
pathways, with complementary mechanisms potentially
producing additive effects opposing disease pathology. In
addition to this restoration of function, memantine also
appears to protect against excitotoxicity and therefore
consequent neurodegeneration.
Clinical Implications
It is well documented that the glutamatergic and cholin-
ergic neuronal systems influence each other, and that their
joint dysfunction is central to the effects produced by AD
pathology. Consequently, the combined use of memantine
and an AChEI to address these two pathological aspects of
AD would appear to be a highly rational approach to
treatment. From a pharmacodynamic perspective, com-
bining two different drug mechanisms is a recognised
means of increasing overall effect size, via a synergistic or
additive interaction. This is schematically illustrated in
Fig. 4, which shows how combining memantine and the
AChEIs could produce a greater clinical effect size without
exceeding the individual dose-limiting boundaries for
either drug. Beyond this, preclinical studies also indicate
that memantine may confer a neuroprotective benefit.
It is interesting to note that in monotherapy, memantine
and the AChEIs appear to have additional positive effects
on some differing behavioural domains—memantine pro-
ducing improvements in agitation/aggression and delusions
(Gauthier et al. 2005), and AChEIs (donepezil) affecting
the domains of depression, anxiety and apathy (Feldman
et al. 2001). This would seem to be further evidence (albeit
Fig. 2 The ‘3-neurone model’ for the action of memantine and the
AChEIs in AD
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indirect) that the two drugs do not act via the same
mechanisms, or exclusively within the same pathways/
brain regions.
In practice, the application of combination treatment in
AD obviously relies upon proven safety and efficacy in the
clinical setting. Drug interaction studies in healthy adults
(Periclou et al. 2004; Yao et al. 2005) and in patients with
AD (Shua-Haim et al. 2008) have shown a lack of phar-
macokinetic interactions between memantine and each of
the AChEIs. Combination treatment has also proven to be
well tolerated in randomised, controlled studies of patients
at all stages of AD (Porsteinsson et al. 2008; Tariot et al.
2004; Grossberg et al. 2008; Howard et al. 2012), as well as
in post-marketing surveillance of dementia patients in
German clinical practice (Hartmann and Mo¨bius 2003).
Indeed, some gastrointestinal side effects of the AChEIs
(diarrhoea, faecal incontinence, nausea) have been reported
less frequently with combination treatment (Tariot et al.
2004) and discontinuation rates after 24 weeks are also
decreased compared with AChEI monotherapy (Porsteins-
son et al. 2008; Tariot et al. 2004). The pooled analysis of
two randomised, controlled 24-week studies has shown a
similar incidence of adverse events in patients treated with
the combination of memantine and donepezil and in
patients treated with placebo and donepezil (Atri et al.
2013). Interestingly, this pooled analysis, performed in
patients with moderate to severe AD, has also shown that
the frequency of agitation was approximately two times
less in the memantine/donepezil combination treatment
group compared to placebo/donepezil group.
In terms of efficacy, several large-scale clinical studies
have included patients receiving combination treatment, and
shown favourable outcomes (Tariot et al. 2004; Atri et al.
2008; Lopez et al. 2009; Grossberg et al. 2008). In one
randomised, double-blind controlled study in 404 patients
with moderate to severe AD, treatment with memantine and
donepezil produced significant benefits across cognitive,
functional, behavioural and global domains, when compared
with donepezil monotherapy (Tariot et al. 2004). Post hoc
analyses of this study revealed the superiority of combina-
tion treatment over AChEI monotherapy in specific areas
such as language and memory (Schmitt et al. 2006), toileting
and higher-level functions (Feldman et al. 2006), and agi-
tation/aggression and irritability (including decreased
symptom emergence) (Cummings et al. 2006; Gauthier et al.
2005). In addition, more patients responded with symptom
improvement or stabilisation in the combination treatment
group than in the group receiving monotherapy with do-
nepezil (van Dyck et al. 2006).
Different results were reported when memantine/AChEI
treatment was investigated in a randomised, double-blind
controlled study in 433 patients with mild to moderate AD,
in which the combination was not found to be statistically
superior to AChEI monotherapy (Porsteinsson et al. 2008).
The apparently contradictory results from these two studies
(Tariot et al. 2004; Porsteinsson et al. 2008) have led to
some uncertainties in recommendation of the combination
treatment as reflected in the EFNS guidelines for the
diagnosis and management of AD (Hort et al. 2010).
However, patients included in the study published by
Porsteinsson et al. (2008) had a mild to moderate degree of
AD compared to moderate to severe disease severity in the
study published by Tariot et al. (2004). It should be noted
that memantine is not approved for the treatment of mild
AD, neither in the European Union nor in the USA or
Japan. In order to address the differences in study popu-
lations of these two studies (Tariot et al. 2004; Porsteinsson
et al. 2008), a post hoc meta-analysis was performed. In
this analysis, in which patients with mild AD were exclu-
ded, significant benefits of the combination treatment
compared to donepezil monotherapy were seen for patients
with moderate to severe AD (Atri et al. 2013). This anal-
ysis provides further support that the combination treat-
ment is the most effective in moderate to severe AD
patients.
Fig. 3 Schematic showing the proposed effect of memantine on the
activity of NMDA
Fig. 4 Schematic illustration of the hypothesised clinical effect size
with combined memantine and AChEI treatment
364 Neurotox Res (2013) 24:358–369
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A randomised, double-blind controlled clinical study
with 677 moderate to severe AD patients which investi-
gated an extended release formulation of memantine 28 mg
in combination with an AChEI compared to AChEI alone
has, again, shown statistically significant treatment effects
favouring combination treatment (Grossberg et al. 2008;
Bassil et al. 2010).
The most recent randomised, controlled clinical study
investigated what happens to the patients with moderate to
severe AD treated with donepezil when: (a) memantine
was added to the existing donepezil therapy (combination
treatment group); (b) existing donepezil monotherapy was
continued (donepezil monotherapy treatment group);
(c) memantine was introduced to the patients and donepezil
was discontinued (memantine monotherapy treatment
group) and (d) donepezil was discontinued without intro-
duction of memantine (placebo treatment group) (Howard
et al. 2012). Due to recruitment difficulties, the initially
calculated sample size of 800 patients had to be reduced to
295 recruited patients. In addition, there was a high and
disproportionate treatment discontinuation rate (approxi-
mately 60 %), leaving only 20 patients in the placebo arm
and 38 patients in the combination arm at end of study
(week 52). Yet, despite these limitations, the best treatment
effects, seen in both primary efficacy parameters (cognition
and activities of daily living), were achieved in the com-
bination treatment group at week 30 and were still present
at week 52 (although no longer statistically significant for
the given small sample size).
Regarding disease progression, pooling clinical data
from two randomised controlled studies showed that
combination therapy could significantly reduce the occur-
rence of marked clinical worsening in patients with mod-
erate to severe AD, as compared with AChEI monotherapy
(Wilkinson and Andersen 2007; Atri et al. 2013). Consis-
tent with this, observational studies found that combination
treatment appeared to slow cognitive and functional
decline in the long term (modelled progression over
4 years vs AChEI treatment alone) (Atri et al. 2008), and
may delay time to nursing home admission (Lopez et al.
2009). Interestingly, an open-label study also showed that
the majority of patients with moderately severe AD, who
had continued cognitive decline with AChEI monotherapy,
responded positively (stable/improved Mini-Mental State
Examination (MMSE) score) upon addition of memantine
(Dantoine et al. 2006).
Based on the results from the available clinical studies,
the authors of a recent clinical review concluded that the
combination therapy for AD seems to be safe, well toler-
ated and may represent the current gold standard for
moderate to severe AD (Patel and Grossberg 2011). In
another recent clinical review Schmidtke et al. (2011) state
that combination therapy with memantine and an AChEI
should be implemented when the patient progresses from
mild to moderate AD. This has been shown in a recent
cohort study, in which 686 patients with mild to moderate
AD from 16 specialised clinics in France were followed for
4 years (Gillette-Guyonnet et al. 2011). Whereas 89 % of
patients were treated with AChEI monotherapy at baseline,
26 % used memantine/AChEI combination therapy by year
4. This is also in accordance with the approved labels, since
in Europe AChEIs are approved for the treatment of
patients with mild AD, whereas both drug groups (AChEIs
and memantine) are approved for moderate AD.
Combination therapy is already considered in the current
clinical practice of AD treatment, but the frequency of its
use differ between countries (Calabrese et al. 2007; Vidal
et al. 2008). Variations in the prescription rates of combi-
nation therapy between different countries reflect real-life
routine clinical practice as well as differences in the
reimbursement status in each country. Combination treat-
ment was found to be cost-effective compared with the use
of an AChEI alone (Lachaine et al. 2011; Weycker et al.
2007) and clinical studies clearly provide evidence for its
usefulness. However, the major stumbling blocks hindering
the recommendation of combination therapy for even more
AD patients seem to be cost and the therapeutically nihil-
istic attitude among many practitioners that current AD
therapies are not worth prescribing (Patel and Grossberg
2011). As a consequence, a large number of AD patients
might be deprived of the currently best possible treatment.
This is of special concern for a devastating condition like
AD, for which no cure exists and for which combining
existing treatments with different modes of action is a valid
approach towards treatment optimisation.
In summary, preclinical data confirm that the combina-
tion of two existing treatment mechanisms—memantine and
an AChEI—may be a useful approach for the management
of AD. The two drugs target different (although intercon-
nected) pathological pathways, and it has been proposed that
their complementary activity may produce greater effects
than either drug alone. This theory has been borne out by
results from the currently available clinical studies of com-
bination therapy, which have demonstrated significant effi-
cacy (beyond that of AChEI monotherapy) and good
tolerability in patients with moderate to severe AD.
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